Please login to the form below

Not currently logged in
Email:
Password:

Biotie

This page shows the latest Biotie news and features for those working in and with pharma, biotech and healthcare.

Acorda acquires Biotie to expand in Parkinson's disease

Acorda acquires Biotie to expand in Parkinson's disease

Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... Biotie also has a royalty stream from Lundbeck's sales of

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    410. Biotie Oy/ Acorda. Acquisition company. CNS portfolio includes tozadenant for Parkinson's in p2b .

  • Pharma deals during September 2012 Pharma deals during September 2012

    Lundbeck has subscribed for 4.6 per cent of Biotie Therapeutics shares for 10m (25 per cent premium to the subscription price). The companies already have a worldwide exclusive licence agreement ... term cash injection, as in August, Biotie had

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics